ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
OSE Immunotherapeutics

OSE Immunotherapeutics (OSE)

6.71
-0.04
(-0.59%)
Closed 14 January 3:30AM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
6.71
Bid
6.70
Offer
6.80
Volume
61,655
6.63 Day's Range 6.85
3.115 52 Week Range 11.58
Market Cap
Previous Close
6.75
Open
6.75
Last Trade
6
@
6.71
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
160,821
Shares Outstanding
21,767,777
Dividend Yield
-
PE Ratio
-6.35
Earnings Per Share (EPS)
-1.06
Revenue
2.23M
Net Profit
-23M

About OSE Immunotherapeutics

Sector
Coml Physical, Biologcl Resh
Industry
Coml Physical, Biologcl Resh
Headquarters
Nantes, Loire-atlantique, Fra
Founded
-
OSE Immunotherapeutics is listed in the Coml Physical, Biologcl Resh sector of the Euronext with ticker OSE. The last closing price for OSE Immunotherapeutics was 6.75 €. Over the last year, OSE Immunotherapeutics shares have traded in a share price range of 3.115 € to 11.58 €.

OSE Immunotherapeutics currently has 21,767,777 shares in issue. The market capitalisation of OSE Immunotherapeutics is 146.93 € million. OSE Immunotherapeutics has a price to earnings ratio (PE ratio) of -6.35.

OSE Latest News

OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer

OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer   NANTES, France, January 13, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE...

OSE Immunotherapeutics annonce la nomination du Dr. Sonya Montgomery au poste de Chief Development Officer

OSE Immunotherapeutics annonce la nomination du Dr. Sonya Montgomery au poste de Chief Development Officer OSE Immunotherapeutics annonce la nomination du Dr. Sonya Montgomery au poste de Chief...

OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer

OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer   NANTES, France, January 13...

Ose Immunotherapeutics : Informations relatives au nombre total de droits de vote et d’actions composant le capital

Ose Immunotherapeutics : Informations relatives au nombre total de droits de vote et d’actions composant le capital Informations relatives au nombre total de droits de vote et d’actions composant...

OSE Immunotherapeutics présentera les résultats d’induction de Phase 2 de l’anti-IL-7R Lusvertikimab dans la rectocolite hémorragique au 20ème congrès de l’ECCO

OSE Immunotherapeutics présentera les résultats d’induction de Phase 2 de l’anti-IL-7R Lusvertikimab dans la rectocolite hémorragique au 20ème congrès de l’ECCO Un abstract clinique sur les...

OSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction Results in Ulcerative Colitis at 20th Congress of ECCO

OSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction Results in Ulcerative Colitis at 20th Congress of ECCO A clinical abstract on the induction results from the CoTikiS...

OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi®

OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi® ARTEMIA: Clinical trial protocol approved globally. Most countries and sites...

OSE Immunotherapeutics annonce des avancées cliniques positives de Tedopi®, son vaccin thérapeutique contre le cancer en développement avancé

OSE Immunotherapeutics annonce des avancées cliniques positives de Tedopi®, son vaccin thérapeutique contre le cancer en développement avancé OSE Immunotherapeutics annonce des avancées cliniques...

OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi®

OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi® OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary...

OSE Immunotherapeutics : Informations Relatives au Nombre Total de Droits de Vote et d’Actions Composant le Capital

OSE Immunotherapeutics : Informations Relatives au Nombre Total de Droits de Vote et d’Actions Composant le Capital Informations Relatives au Nombre Total de Droits de Vote et d’Actions Composant...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.88-11.59420289867.597.626.631140826.91906535DE
4-1.02-13.19534282027.737.876.631119047.15875097DE
12-3.2-32.29061553999.9111.586.631608218.89667243DE
26-0.48-6.675938803897.1911.586.421813268.30483523DE
522.6464.86486486494.0711.583.1151735077.20267149DE
156-3.59-34.85436893210.311.582.7051084826.33336947DE
2602.8674.28571428573.8515.452.7051028367.41624835DE

OSE - Frequently Asked Questions (FAQ)

What is the current OSE Immunotherapeutics share price?
The current share price of OSE Immunotherapeutics is 6.71 €
How many OSE Immunotherapeutics shares are in issue?
OSE Immunotherapeutics has 21,767,777 shares in issue
What is the market cap of OSE Immunotherapeutics?
The market capitalisation of OSE Immunotherapeutics is EUR 146.93M
What is the 1 year trading range for OSE Immunotherapeutics share price?
OSE Immunotherapeutics has traded in the range of 3.115 € to 11.58 € during the past year
What is the PE ratio of OSE Immunotherapeutics?
The price to earnings ratio of OSE Immunotherapeutics is -6.35
What is the cash to sales ratio of OSE Immunotherapeutics?
The cash to sales ratio of OSE Immunotherapeutics is 65.59
What is the reporting currency for OSE Immunotherapeutics?
OSE Immunotherapeutics reports financial results in EUR
What is the latest annual turnover for OSE Immunotherapeutics?
The latest annual turnover of OSE Immunotherapeutics is EUR 2.23M
What is the latest annual profit for OSE Immunotherapeutics?
The latest annual profit of OSE Immunotherapeutics is EUR -23M
What is the registered address of OSE Immunotherapeutics?
The registered address for OSE Immunotherapeutics is 22 BOULEVARD DE BENONI GOULLIN, NANTES, LOIRE-ATLANTIQUE, 44200
What is the OSE Immunotherapeutics website address?
The website address for OSE Immunotherapeutics is www.ose-immuno.com
Which industry sector does OSE Immunotherapeutics operate in?
OSE Immunotherapeutics operates in the COML PHYSICAL, BIOLOGCL RESH sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
HYPDSHipay Group DS
0.0024 €
(200.00%)
1.83k
ALCYBCybergun
0.0002 €
(100.00%)
16.61M
BNBSTonner Drones
0.0015 €
(50.00%)
100
ALLPLLepermislibre SA
0.60 €
(50.00%)
27.77k
ALVGVEOM Group
0.16 €
(22.14%)
87.97k
ALTHETheraclion
0.23 €
(-17.86%)
34.88k
MLPACPacte Novation
8.35 €
(-14.80%)
3
ALALOAcheterLouerFR
0.0958 €
(-12.91%)
121.44k
MLVIRVirtualware 2007 SA
7.40 €
(-11.90%)
150
MLBONBonyf NV
15.90 €
(-11.67%)
105
ATOAtos SE
0.0022 €
(10.00%)
2.22B
BCPBanco Comercial Portugues SA
0.4802 €
(0.00%)
49.83M
ALVERVergnet
0.0017 €
(-5.56%)
18.84M
ALCYBCybergun
0.0002 €
(100.00%)
16.61M
INGAING Groep NV
15.538 €
(3.17%)
14.34M

Discussion

View Full Feed
PutzMueler PutzMueler 2 minutes ago
Minimal. The point is the blockage at $1.66
NB
BottomBounce BottomBounce 2 minutes ago
$NIO Nio (NIO) delivered a "new monthly high" of 31,138 vehicles in December, up 73% from last year. It delivered 20,610 of its premium smart EVs and 10,528 of its family-oriented smart EV brand, ONVO. Nio's fourth-quarter deliveries rose 45% year over year to 72,689 vehicles, representing a "quarte
NIO
PennyStockTrader2 PennyStockTrader2 2 minutes ago
maybe but I picked up another 100K today. When it blows, it could blow hard, or not, but we should see a bottom around here somewhere. Weak hands to strong.
IPSI
stark12 stark12 2 minutes ago
https://www.marketbeat.com/instant-alerts/hc-wainwright-lowers-niocorp-developments-nasdaqnb-price-target-to-325-2025-01-13/

This strikes me as pathetic, especially since we have never achieved the price target Wainwright has set.
NB
Invest-in-America Invest-in-America 2 minutes ago
PHIO: A Mecca-Godzilla-Class CONGRATS to all here who scored way bigger than I did today on THIS puppy!!! (But I made some nice bank, anyway; but nothing to boast about.)
PHIO
BottomBounce BottomBounce 2 minutes ago
$NIO Nio (NIO) delivered a "new monthly high" of 31,138 vehicles in December, up 73% from last year. It delivered 20,610 of its premium smart EVs and 10,528 of its family-oriented smart EV brand, ONVO. Nio's fourth-quarter deliveries rose 45% year over year to 72,689 vehicles, representing a "quarte
NIO
georgie18 georgie18 3 minutes ago
TANH...Added 15s/16s today...🥳

georgie18

Member Level
Re: None

Thursday, January 09, 2025 11:01:09 AM

Post#
670930
of 671238
TANH...18...🥳... https://schrts.co/tyrKuzDT ...Looking for Break/Hol
TANH
88TH MAN 88TH MAN 3 minutes ago
I am holding all my shares, and I know what, when, where, and why.
FBEC
Chartmaster Chartmaster 3 minutes ago
Just saw 407 AH!!!!
TSLA
georgie18 georgie18 3 minutes ago
TANH...Added 15s/16s today...🥳

georgie18

Member Level
Re: None

Thursday, January 09, 2025 11:01:09 AM

Post#
670930
of 671238
TANH...18...🥳... https://schrts.co/tyrKuzDT ...Looking for Break/Hol
TheRealMrPirate TheRealMrPirate 3 minutes ago
YIKES! The FKA board is alive.
Must mean you're golden. 2025$ 💩
I responded to you, do you feel better now?
bubba412 bubba412 3 minutes ago
You don’t know sht Stop your BS It’s getting very old!!
ELTP
georgie18 georgie18 3 minutes ago
TANH...Added 15s/16s today...🥳

georgie18

Member Level
Re: None

Thursday, January 09, 2025 11:01:09 AM

Post#
670930
of 671238
TANH...18...🥳... https://schrts.co/tyrKuzDT ...Looking for Break/Hol
$PennyMover $PennyMover 3 minutes ago
I just don't understand why we have such a large amount of shares on the ask
GRLF
fung_derf fung_derf 4 minutes ago
LOL....Schindler's List with shorts??

https://c8.alamy.com/comp/MN8YCG/1950s-two-young-bavarian-boys-stand-together-on-a-dusty-track-outside-a-village-in-the-alps-germany-wearing-traditional-clothes-of-the-era-short-leather-breeches-or-lederhosen-MN8YCG.jpg
SMCI
surfkast surfkast 4 minutes ago
I got out today. Something stinks here. Got back in when it hit $7.44 a few months ago and grabbed a few moire but not playing here. Will wit and see if the $3.00 train comes in. So sad.
IOVA
RKMKE RKMKE 4 minutes ago
Nice close!
GEVI
price_and_volume price_and_volume 4 minutes ago
Why not?
Authorized Shares: Unlimited $VXIT hands out shares like candy at a parade. End of FY 2023: 2,844,828,058 shares issued and outstanding
End of FY 2024: 3,619,383,614 shares issued and outstanding. Quite the trajectory lately - once it starts it typically accelerates & ends in
VXIT
NASA11 NASA11 4 minutes ago
As long as they pull the rug during market hours and stops can get executed close to the stops (with this liquidity). It's the gap down that would wreck this. Hopefully any news comes out during market hours.
FNMA
Prudent Capitalist Prudent Capitalist 4 minutes ago
I was not watching at the time to see how many shares traded at $1.66
NB
IhidfromtheX IhidfromtheX 5 minutes ago
They're just keeping Doc on his toes...The guesses keep going!
AVXL
nymphtyer nymphtyer 5 minutes ago
There was a time that only myself and Mugsy were posting on this board, now there are dozens. We have just stared on this move. I have now paid for my entire stake in UMAV and still have a nice chunk of free shares. Believe me. Dollars per share are coming. Patience is the key. Let the news unfold.
UMAV
capgain capgain 5 minutes ago
Since You're Gone (2016 Remaster)

https://www.youtube.com/watch?v=FqHIkkRrwcQ
ducci1 ducci1 5 minutes ago
Tuesday---SPX Testing Resistance at Pivot 5841 & 5 min Red Line ( 5844) Need take out for Turn ?? !!LOL!!
SPY

Your Recent History

Delayed Upgrade Clock